HCWB · HCW Biologics Inc.
$2.57
-0.08 (-3.02%)
At close · Jul 28
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements and that the substantial doubt that existed in its going concern analysis was not alleviated.”View the 10-Q filed May 14, 2026
Market Cap
$17.41M
Shares
6.73M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | CEO | $438,656 |
| Rebecca Byam | CFO | $309,309 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $263,895 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | CEO | $368,188 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $261,667 |
| Rebecca Byam | CFO | $154,236 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | CEO | $425,880 |
| Rebecca Byam | CFO | $330,300 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $251,160 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | CEO | $421,050 |
| Rebecca Byam | CFO | $297,080 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $248,570 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | CEO | $2,972,838 |
| Rebecca Byam | CFO | $982,140 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $297,769 |